

SIGNIFICANT IMPROVEMENT IN MELANOMA SURVIVAL OVER THE LAST DECADE: A HUNGARIAN NATIONWIDE STUDY BETWEEN 2011–2019

Gabriella Liskay^{1*}, Angela Benedek^{2*}, Csaba Polgár¹, Judit Oláh⁴, Péter Holló⁵, Gabriella Emri⁶, András Csejtei⁷, István Kenessey¹, Zoltán Polányi², Kata Knollmayer², Máté Várnai^{2,3}, Zoltán Vokó³, Balázs Nagy³, György Rokszin⁸, Ibolya Fábián^{8,9}, Zsófia Barcza¹⁰, Rolland Gyulai^{11*}, Zoltan Kiss^{2*}

1. National Institute of Oncology, Budapest, Hungary
2. MSD Pharma Hungary Ltd., Budapest, Hungary
3. Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary
4. Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary
5. Department of Dermatology, Venereology and Dermatocology, Semmelweis University, Budapest, Hungary
6. Department of Dermatology, University of Debrecen, Debrecen, Hungary
7. Department of Oncoradiology, Markusovszky University Teaching Hospital, Szombathely, Hungary
8. RxTarget Ltd., Szolnok, Hungary
9. University of Veterinary Medicine, Budapest, Hungary
10. Syntesia Medical Communications Ltd., Budapest, Hungary
11. Department of Dermatology, Venereology and Oncodermatology, Faculty of Medicine, University of Pécs, Pécs, Hungary

* Gabriella Liskay and Angela Benedek equally contributed to this work

** Rolland Gyulai and Zoltan Kiss equally contributed to this work

Corresponding author: Zoltán Kiss MD, MSD Pharma Hungary Ltd., 1095 Lechner Ö. fs 8. Budapest, Hungary, zoltan_kiss2@merck.com, +36-30-681-7524

ABSTRACT

Background Recent real-world studies have reported significant improvements in the survival of malignant melanoma in the past few years, mainly as a result of modern therapies. However, long-term survival data from Central Eastern European countries such as Hungary are currently lacking.

Methods This nationwide, retrospective study examined melanoma survival in Hungary between 2011–2019 using the databases of the National Health Insurance Fund (NHIF) and Central Statistical Office (CSO) of Hungary. Crude overall survival and age-standardized 5-year net survival as well as the association between age, sex, and survival were calculated.

Results Between 2011 and 2019, 22,948 newly diagnosed malignant melanoma cases were recorded in the NHIF database (47.89% male, mean age: 60.75 years (SD: ± 16.39)). 5-year overall survival was 75.40% (women: 80.78%; men: 69.52%). Patients diagnosed between 2017–2019 had a 20% lower risk of mortality compared to patients diagnosed between 2011–2012 (HR 0.80, 95% CI 0.73–0.89; $p < 0.0001$). Age-standardized 5-year net survival rates in 2011–2014 and 2015–2019 were 90.6% and 95.8%, respectively (women: 93.1% and 98.4%, men: 87.8% and 92.7%, respectively). The highest age-standardized 5-year net survival rates were found in the 0–39 age cohort (94.6% in the 2015–2019 period).

Conclusion Hungary has similar melanoma survival rates to Western European countries. Based on net survival, the risk of dying of melanoma within 5 years was cut by more than half (55%) during the study period, which coincides with the successful implementation of awareness campaigns and the wide availability of modern therapies.

KEYWORDS: malignant melanoma, net survival, age, sex

Running title: Improvement in melanoma survival in Hungary

INTRODUCTION

Melanoma has relatively low incidence compared to other non-melanoma cancers of the skin; however, it is responsible for the majority of skin cancer-related mortality (1,2,3,4). Although the number of new cases has been rising in fair-skinned populations and represents significant disease burden (5), some recent publications have indicated a change in trends in mortality over the last decade (6,7). Multiple prognostic factors have been associated with survival in melanoma including age, sex, anatomic site, ulceration, or stage (8,9). Female sex is a positive prognostic factor in melanoma, which is demonstrated by a number of studies showing better survival among women compared to men (10,11). Furthermore, other pathological characteristics such as melanoma thickness (Breslow thickness) are also strongly related to the survival, with thinner lesions having better survival rates than thicker lesions (5).

The incidence and mortality of melanoma varies across European countries. 2018 GLOBOCAN data show wide variations in melanoma incidence and mortality across Europe, with lower incidence and similar mortality rates in Central Eastern European (CEE) countries compared to Western Europe (12). However, apart from differences in UV exposure and preventive activities, the observed lower incidence in CEE countries may also be attributed to suboptimal cancer registration and the lack of centralized cancer registries in some countries (13). Over the past 10 years, survival in advanced melanoma has significantly improved, mainly as a result of modern therapies including immunotherapy and targeted agents (14,15,16,17). The global CONCORD-3 cancer survival surveillance programme compared 5-year net survival rates of melanoma between countries based on registry data. During 2010–2014, 5-year net survival varied between 70%–85% in Central Eastern European countries (CEEC), with modest improvements compared to CONCORD-2 results from 2005–2009 (65%–85%) (18). However, the CONCORD-3 database contains no data from Hungarian registries.

Therefore, our nationwide, retrospective study aimed to investigate 5-year net survival of the total Hungarian melanoma population between 2011–2019, compare it to international results, and evaluate changes in survival during this period. The impact of age and sex on survival as well as on the change of survival rates was also examined.

MATERIALS AND METHODS

Data sources

Our nationwide, retrospective study used data from the Hungarian National Health Insurance Fund (NHIF) and the Central Statistical Office (CSO). The NHIF database covers almost the entire Hungarian population and contains information on prescription claims, in- and outpatient visits and medical procedures, as well as medical information using ICD-10 codes. The CSO database provides data on age- and sex-specific mortality from all Hungarian citizens annually. The study was approved by the National Ethical Committee (IV2581-2/2020/EKU). Our study included melanoma patients (ICD-43) diagnosed between January 1, 2011 and December 31, 2019, who were ≥ 20 years old at the time of diagnosis and had 2 occurrence of C43 ICD-10 codes. A reference period was set from 2009 to 2010 to accurately identify newly diagnosed melanoma patients as it helped to exclude patients with prevalent melanoma at the start of the time window by excluding those with a prior diagnosis code. Patients who died within 60 days of the first C43 code record were also included. Newly diagnosed melanoma patients were followed until December 31, 2019 or until the time of death which was available from the NHIF database without the cause of death. We expressed overall survival (OS) of melanoma population by sex, age and study years based on NHIF database as well as calculated the net survival using NHIF and CSO database inputs using the Pohar Perme estimation.

Statistical analysis

Data collected were anonymous and non-identifiable. Newly diagnosed melanoma patients are presented as crude incidence numbers on a yearly basis (n). Mean ages were determined for the total time period and for the different diagnostic time intervals (2011–2012, 2013–2014, 2015–2016, 2017–2019). Crude numbers and mean age are shown for both sexes separately and together. 5-year net survival rates were used for international comparison with CONCORD-3 study results. Net survival corresponds to the cumulative probability of surviving up to a given time since diagnosis (e.g., 5 years) after correcting for other causes of death (as background mortality). Net survival was calculated using the Pohar Perme estimation reported in the CONCORD-3 study, which takes unbiased account of the higher competing risks of death in the elderly (18). We excluded those from the analysis who exceed the age of 95, as Pohar Perme estimation could not calculate 5 year survival within this population. Overall survival is presented using Kaplan-Meier curves. The association between sex, age, and survival was estimated by Cox regression models. We used Cox regression to calculate the age-adjusted hazard ratio (HR) of death of patients diagnosed between 2011–2014 and 2015–2019. All calculations were performed using R version 3.6.1 (05/07/2019) with package boot version 1.3-20.

RESULTS

Study population and patient characteristics

In total, 22,948 newly diagnosed malignant melanoma cases were recorded in the NHIF database between 2011 and 2019 (2011–2012: n=4,786; 2013–2014: n=5,060; 2015–2016: n=5,487; 2017–2019: n=7,615) (**Table 1**). In total, 47.89% of patients were male (range: 47.60%–48.13%). The mean age at the time of diagnosis was 60.75 (SD: ± 16.39), varying between 63.09 (SD: ± 15.20) and 58.01 (SD: ± 17.38) years in the male and female population during the investigation period. The highest proportion of cases were found in the 60–69 age group (n=5,445; 23.73% of total), followed by the 70–79 age group (n=5,225; 22.77% of total).


Table 1 Patient characteristics according to study periods. SD: standard deviation

	2011-2012		2013-2014		2015-2016		2017-2019		Total	
Patients with new diagnosis (n)	4,786		5,060		5,487		7,615		22,948	
Male (n, % of melanoma patients)	2,278	47.60%	2,422	47.87%	2,625	47.84%	3,665	48.13%	10,990	47.89%
Female (n, % of melanoma patients)	2,508	52.40%	2,638	52.13%	2,862	52.16%	3,950	51.87%	11,958	52.11%
Mean age at diagnosis (y, mean \pmSD)	60.95	± 16.17	60.62	± 16.47	60.44	± 16.57	60.93	± 16.34	60.75	± 16.39
Male (y, mean \pm SD)	62.18	± 15.38	62.14	± 15.69	63.09	± 15.20	62.85	± 15.46	62.61	± 15.44
Female (y, mean \pm SD)	59.83	± 16.77	59.22	± 17.04	58.01	± 17.38	59.14	± 17.93	59.03	± 17.04
Mean follow-up (month, mean \pmSD)										
Total	75.24	± 33.04	59.28	± 22.93	42.11	± 13.79	16.90	± 10.22	44.44	± 30.39
Male	70.81	± 35.20	56.90	± 24.14	40.37	± 14.94	16.83	± 10.26	42.47	± 30.10
Female	79.27	± 30.41	61.47	± 21.54	43.71	± 12.43	16.96	± 10.19	46.25	± 30.53
Age groups										
20-39	610	12.75%	711	14.05%	768	14.00%	899	11.81%	2,988	13.02%
40-49	548	11.45%	612	12.09%	738	13.45%	1,155	15.17%	3,053	13.30%
50-59	868	18.14%	780	15.42%	817	14.89%	1,074	14.10%	3,539	15.42%
60-69	1,147	23.97%	1,199	23.70%	1,286	23.44%	1,813	23.81%	5,445	23.73%
70-79	1,057	22.09%	1,159	22.91%	1,238	22.56%	1,771	23.26%	5,225	22.77%
80 \leq	556	11.62%	599	11.84%	640	11.66%	903	11.86%	2,698	11.76%
Regions										
Central Hungary	1,557	32.53%	1,747	34.53%	1,841	33.55%	2,636	34.62%	7,781	33.91%
Northern Hungary	517	10.80%	560	11.07%	695	12.67%	922	12.11%	2,694	11.74%
Northern Great Plain	565	11.81%	563	11.13%	626	11.41%	827	10.86%	2,581	11.25%
Southern Great Plain	739	15.44%	770	15.22%	759	13.83%	1,000	13.13%	3,268	14.24%
Central Transdanubia	496	10.36%	520	10.28%	555	10.11%	741	9.73%	2,312	10.07%
Southern Transdanubia	429	8.96%	425	8.40%	449	8.18%	634	8.33%	1,937	8.44%
Western Transdanubia	483	10.09%	475	9.39%	562	10.24%	855	11.23%	2,375	10.35%

Mean follow-up time for those diagnosed between 2011 and 2012 was 75.24 (SD: ± 33.04) months, while for those within the 2017-19 period, this value was 16.90 (SD: ± 10.22) months. Incidence of melanoma was the highest among patients living in Central Hungary Region (33.91% overall) and lowest in Southern Transdanubia Region (8.44%).

Long-term crude overall survival

Figure 1 Estimated overall survival of Hungarian malignant melanoma patients between 2011 and 2019




At the end of the first year, 92.3% of the total melanoma population was alive (n=22,948). OS rates at 2 years and 5 years were 86.54%, and 75.40%, respectively (**Figure 1**). OS was higher among female patients than male patients throughout the whole study period. 1-year, 2-year, and 5-year OS rates were 93.88%, 89.49%, and 80.78% among female patients, and 90.58%, 83.33%, 69.52% among male patients, respectively. Detailed survival rates of different age cohorts and main Hungarian regions are presented in **Supplementary Table 1**.

Change in crude overall survival between 2011–2012 and 2017–2019

Figure 2 shows overall survival among patients diagnosed between 2011–2012 and 2017–2019. In the 2011–2012 period, newly diagnosed melanoma patients had 1-year, 2-year, and 3-year OS rates of 90.85%, 84.66%, and 80.78%, respectively. Corresponding values in the 2017–2019 period were 92.90%, 87.28%, and 83.52%, respectively.

Figure 2 Overall survival of melanoma patients diagnosed between 2011-12 and 2017-2019



Melanoma patients diagnosed between 2017–2019 had a 20% lower risk of mortality compared to patients diagnosed between 2011–2012 (HR 0.80, 95% CI 0.73–0.89; $p < 0.0001$). Male patients had a larger decrease in mortality (HR 0.78, 95% CI 0.69–0.89; $p < 0.001$) compared to female patients (HR 0.84, 95% CI 0.72–0.98; $p = 0.024$) (**Figure 3**). The largest reduction in mortality was seen in the 50–59 age cohort (HR 0.43, 95% CI 0.31–0.61; < 0.0001); the 60–69 and 85+ age cohorts had non-significant decreases in mortality. The largest mortality reduction was found among patients living in the Central Transdanubian region (HR 0.65, 95% CI 0.43–0.98, $p = 0.04$), and non-significant decreases were seen in Northern Hungary, the Southern Great Plain, and Southern Transdanubia.





Figure 3 Hazard ratio of overall survival of melanoma patients by age and sex diagnosed between 2011-12 and 2017-2019

Age-standardized 5-year net survival of Hungarian melanoma patients

Figure 4 Age-standardized 5-year net survival of Hungarian melanoma patients overall and by sex diagnosed between 2011–2014 and 2015–2019



Age-standardized 5-year net survival rates in 2011–2014 and 2015–2019 were 90.59% and 95.78%, respectively. Corresponding values were 93.13% and 98.36% among female and 87.78% and 92.67% among male patients, respectively (**Figure 4**). The increase in net survival between the 2015-2019 and 2011-2014 periods was significant in the case of the total and female populations (p-value<0.001at both cases), however did not reach statistical significance in the male melanoma population (p=0.095).

Age-standardized 5-year net survival of age cohorts and main Hungarian regions are detailed in **Supplementary Table 2**.

Supplementary Table

Supplementary Table 1 Estimated overall survival of Hungarian malignant melanoma patients between 2011 and 2019 by age, sex and main Hungarian regions

	1 year	2 years	3 years	5 years	8 years
Total	92.30%	86.54%	82.20%	75.40%	67.25%
Age					
20 - 39	98.61%	96.90%	95.97%	94.60%	93.20%
40 - 49	97.37%	94.57%	93.31%	91.17%	88.35%
50 - 59	94.25%	90.58%	87.36%	83.17%	77.64%
60 - 69	92.54%	87.60%	83.72%	77.34%	70.58%
70 - 79	90.24%	82.54%	76.71%	66.24%	51.58%
80≤	80.55%	66.27%	55.15%	39.84%	24.43%
Male	90.58%	83.33%	77.83%	69.52%	60.07%
Female	93.88%	89.49%	86.23%	80.78%	73.85%
Central Hungary	92.09%	87.00%	82.71%	75.75%	66.78%
Northern Hungary	91.52%	85.41%	80.04%	72.28%	64.11%
Northern Great Plain	91.42%	84.15%	78.73%	71.59%	64.75%
Southern Great Plain	91.47%	86.26%	82.20%	75.55%	67.88%
Central Transdanubia	93.40%	87.88%	83.93%	77.61%	69.51%
Southern Transdanubia	91.50%	85.45%	81.61%	74.45%	65.54%
Western Transdanubia	92.53%	86.85%	82.82%	76.06%	67.15%

Supplementary Table 2 Age-standardized 5-year net survival of Hungarian melanoma patients overall, by sex, age cohorts and main regions diagnosed between 2011–2014 and 2015–2019

	2011-2014			2015-2019			Change	
	5 year surv	95% CI		5 year surv	95% CI		Absolute	p-value
Total	90.59%	(89.27% - 91.93%)		95.78%	(93.94% - 97.66%)		5.19%	0.000
Age								
20 - 39	94.36%	(93.08% - 95.66%)		95.68%	(94.21% - 97.17%)		1.32%	0.126
40 - 49	91.18%	(89.40% - 93.00%)		94.90%	(93.40% - 96.42%)		3.72%	0.008
50 - 59	85.98%	(83.98% - 88.03%)		91.51%	(89.18% - 93.90%)		5.53%	0.000
60 - 69	86.64%	(84.71% - 88.62%)		88.37%	(85.23% - 91.63%)		1.73%	0.158
70 - 79	85.72%	(83.09% - 88.44%)		90.98%	(87.32% - 94.79%)		5.26%	0.055
80≤	107.72%	(98.72% - 117.53%)		126.83%	(113.07% - 142.26%)		19.11%	0.717
Male	87.78%	(85.70% - 89.91%)		92.67%	(89.99% - 95.43%)		4.89%	0.095
20-59	85.41%	(83.53% - 87.34%)		90.81%	(88.66% - 93.01%)		5.40%	0.000
60≤	89.20%	(86.04% - 92.47%)		93.36%	(89.37% - 97.54%)		4.16%	0.842
Female	93.13%	(91.48% - 94.80%)		98.43%	(95.90% - 101.01%)		5.30%	0.000
20-59	93.69%	(92.57% - 94.82%)		96.03%	(94.98% - 97.09%)		2.34%	0.006
60≤	92.65%	(89.75% - 95.63%)		101.12%	(96.19% - 106.31%)		8.47%	0.006
Central Hungary	94.12%	(91.96% - 96.33%)		100.00%	(96.60% - 103.51%)		5.88%	0.064
Northern Hungary	84.28%	(80.55% - 88.19%)		94.19%	(89.95% - 98.63%)		9.91%	0.004
Northern Great Plain	84.16%	(80.55% - 87.94%)		89.20%	(84.61% - 94.04%)		5.04%	0.081
Southern Great Plain	91.36%	(87.33% - 95.58%)		96.07%	(90.06% - 102.49%)		4.71%	0.219
Central Transdanubia	87.95%	(84.31% - 91.75%)		100.27%	(95.33% - 105.45%)		12.32%	0.011
Southern Transdanubia	96.00%	(91.18% - 101.08%)		89.25%	(84.08% - 94.74%)		-6.75%	0.233
Western Transdanubia	88.56%	(84.82% - 92.47%)		88.41%	(83.23% - 93.92%)		-0.15%	0.810

DISCUSSION

Our nationwide, retrospective study was the first to examine long-term survival of melanoma in Hungary. Results show that melanoma net survival in Hungary was similar to that of Western European countries during the early 2010's. We demonstrated a significant mortality reduction of melanoma patients between the 2011–2012 and 2017–2019 periods. Furthermore, we also found that female sex and younger age were associated with better survival. Age-standardized 5-year net survival of melanoma also improved considerably during the study period in total and for females.

Improvements in melanoma survival have been reported by a number of recent real-world studies (14,19,20,21,22), the reasons for which are multifactorial. First, the improvement of diagnostic modalities has allowed for an earlier detection of the disease and thus the timely initiation of life-prolonging therapy. Furthermore, the widespread implementation of melanoma awareness campaigns and screening programs worldwide has also contributed to earlier detection and better prognosis. Australia, one of the most affected countries, has conducted a number of successful educational and awareness campaigns starting from the 1980s (23). In the randomized Healthy Text study, theory-based text messages about skin cancer prevention and skin self-examination resulted in significant improvements in sun-protection and skin self-examination behaviors among people aged 18–42 years (24). The SunSmart skin cancer prevention program was initiated in 1988 with a view to raise public awareness, promote preventive behaviors and environmental change for skin cancer prevention. SunSmart resulted in a rapid increase in the use of sun protection and contributed to a reduction in melanoma in younger age groups (25). In Europe, the Euromelanoma Skin Cancer Prevention Campaign was founded in 1999 by six Belgian dermatologists and is now active in 33 European countries with public awareness campaigns and melanoma screening days, scientific publications and special events (www.euromelanoma.org). The Euromelanoma initiative has raised greater awareness of melanoma and increased the number of screenings and the detection of clinically suspected lesions (26,27). Increasing community awareness of melanoma and its risk factors was associated with a progressive decreasing incidence of thicker melanoma and for a long-term decrease in

mortality according to the experience of some countries such as Germany, Australia and the United States (22).

Accordingly, the majority of recent real-world studies have directly linked improvements in melanoma survival to the introduction of modern therapies (14,16,2,21). We found better overall survival rates among female vs. male patients in the Hungarian melanoma population during the whole study period, which is also in line with previous observations (28,29).

To our knowledge, our study is the first to report 5-year net survival rates of melanoma in Hungary based on the database of the CSO. Age-standardized 5-year net survival of melanoma increased from 90.6% in 2011–2014 to 95.8% in 2015–2019, with higher survival rates observed in women and in younger age cohorts during the whole study period. To compare our results with findings from other countries, we examined data from the worldwide CONCORD cancer survival surveillance program for the period of 2011–2014 (18). Age-standardized 5-year net survival of melanoma in Hungary was comparable to that of Western and Northern European countries including Denmark, Sweden, the United Kingdom, Belgium, France, Germany, the Netherlands, and Switzerland where 5-year survival rates also exceeded 90% in this period. This is in line with our previous findings showing that melanoma mortality in Hungary is close to the European average (6) and reflects the effectiveness of the successful local implementation of the Euromelanoma program in 2009 (30). In the interest of high-quality comprehensive cancer control, Hungarian healthcare organisations implemented recommendations for high-quality patient care in melanoma management according to progressivity (31) and nominated 7 clinics as “Melanoma Centres” to promote clinical experience with modern immune and targeted therapies (32). Furthermore, almost the entirety of the Hungarian population is covered by social insurance with full access to reimbursed therapies and has equity in patient care.

The favourable changes in mortality may be attributed to several factors including the relatively high and early access to innovative therapies and high health expenditure per capita compared to neighboring European countries (33). In addition, earlier detection may also contribute to improvements in prognosis, which is supported by a study reporting a significant decrease in mean Breslow thickness from 2.2 mm in 1998 to 1.6 mm in 2008 (34). Finally, the wide availability of modern oncologic diagnostic and treatment modalities in Hungary is likely a key driver of

favorable melanoma outcomes. The introduction of modern therapies has dramatically changed the landscape for melanoma (35,36). Ipilimumab was the first immunotherapy agent approved for the treatment of irresectable, metastatic melanoma by the European Medicines Agency (EMA) in 2012 and followed by the first targeted therapy in 2014. Immunotherapy has revolutionized the treatment of cancers. Pembrolizumab, nivolumab and nivolumab/ipilimumab combination therapy gained approvals in melanoma and in several tumor types over time (37,38). These innovative drugs became available in Hungary shortly after their approval in the European Union, and the period of their introduction coincides with a period of similar survival improvements in Hungary compared to other European countries.

We found higher 5-year net survival rates among female melanoma patients compared to men throughout the whole study period. Our findings are consistent with those reported by the Cancer Research UK database which reported 5-year net survival rates of 92.4% in women and 87.6% in men in the 2010–2011 period (39). The survival advantage of women in melanoma is well-established (10,40,41). A recent large analysis from the U.S. Surveillance, Epidemiology, and End Results (SEER) cancer database showed significantly better 3- and 5-year cancer-specific melanoma survival rates among women compared to men (40), and Behbanani *et al.* also reported better 5-year overall survival for female melanoma patients based on the U.S. National Cancer Registry (10). The positive prognostic significance of female sex may be explained by various factors. Several reports suggest that gender disparities in melanoma survival may partly be due to gender-related differences in skin cancer risk awareness, protection against UV exposure, and self-examination (42,43,44). Furthermore, women have been shown to have a slower rate of growth of the primary tumor and a lower risk of metastasis (45). Recent reports suggest that apart from differences in gender-related behavior, genetic and epigenetic aspects as well as environmental and biological factors may also play an important part in the positive prognostic significance of female sex in melanoma survival (46,47). In our earlier report, we demonstrated the Hungarian mortality-to-incidence ratios showed a decrease over the past decade in both sexes and reached the level of Western and Northern European countries, although males had higher MIRs in all study years in comparison with women (48).

Our study corresponds well with the growing body of evidence showing gender-related differences in melanoma survival in the era of modern therapies and warrants further investigations into potentially modifiable risk factors responsible for poorer prognosis among men compared to women.

In our study, younger age groups had better 5-year net survival rates than older patients. Specifically, the highest survival rate was seen for patients aged 0–39 years (95%), while the lowest rate was found for the 70–79 age cohort (87.3%). The better prognosis of melanoma among younger ages is well-documented (49), and our findings are also in line with data from the Cancer Research UK database showing a continuous decrease in 5-year net overall survival with increasing age (50). While better survival rates in younger ages may partly be explained by the generally better health status of these age groups, several reports suggest that other factors also play a part in the survival gap. First, older patients present with significantly thicker melanomas, a higher mitotic rate and increased incidence of ulceration compared to young patients (51,52,53). Although a declining trend in Breslow thickness has been reported recently, the decline seems to be less prominent in older patients compared to young patients, reflecting poorer prognosis for the elderly (52). Besides melanoma thickness, older patients are more often diagnosed with head and neck melanomas and nodular lesions which develop very quickly and are associated with poor prognosis (54). Elderly patients may have gained less advantage from public health campaigns and thus have lower risk awareness and thus later (self-)detection (51), and suboptimal staging and/or treatment may also contribute to poorer prognosis (54). Furthermore, they are often not considered candidates for surgical treatment, resulting in a lower excision rate and longer time to definitive excision of primary melanoma (54,55). Besides, aging of immune system could contribute to the higher incidence of malignancies, more aggressive form of certain cancer types and worse response for given therapies, which could result in worse outcomes (56). In summary, there is still room for improvement in melanoma management among the elderly to ensure that they benefit more from newly available treatment options.

The main strengths and limitations of our analysis both lie in the nature of the NHIF database, which allowed for the inclusion of all Hungarian melanoma patients diagnosed between 2011

and 2019, however does not contain any information on patient clinical characteristics, vital signs, laboratory findings, or baseline prognostic features.

CONCLUSION

This study was the first to examine long-term overall survival and 5-year net survival of melanoma in Hungary. The results show that melanoma survival in Hungary is similar to that of Western European countries. We found better survival rates in women and younger age groups, and based on net survival, the risk of dying of melanoma within 5 years was cut by more than half (55%) during the study period, which coincides with the successful implementation of awareness campaigns and the wide availability of modern therapies.

ACKNOWLEDGEMENTS

We would like to thank the NHIF and CSO as well as the National Cancer Registry for providing comprehensive datasets for our analysis. We would also like to thank Zsófia Barcza of Syntesia Medical Communications for medical writing support.

FUNDING

The authors declare that this study received funding from MSD Pharma Hungary. The funder had the following involvement with the study: in study design, data collection and analysis, decision to publish, and preparation of the manuscript.

CONFLICT OF INTEREST STATEMENT

Authors ZK, ZP, MV, AB and KK were employed by the company MSD Pharma Hungary. MV, BN and ZV are employees of Semmelweis University. Semmelweis University received a grant from MSD Pharma Hungary to contribute to this research. GyR and IF are employees of RxTarget Ltd. and ZsB is employed of Syntesia Ltd. where their contribution to this project was financially compensated. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

AVAILABILITY OF DATA AND MATERIALS

Data sharing is available in supplementary tables and figures, and the authors are happy to share all available data from the study.

REFERENCES

1. Giblin AV, Thomas JM. Incidence, mortality and survival in cutaneous melanoma. *J Plast Reconstr Aesthet Surg*. 2007;60(1):32-40.
2. Miller AJ, Mihm MC Jr. Melanoma. *N Engl J Med*. 2006 Jul 6;355(1):51-65.
3. Arnold M, Holterhues C, Hollestein LM, Coebergh JW, Nijsten T, Pukkala E, Holleczeck B, Tryggvadóttir L, Comber H, Bento MJ, Diba ChS, Micallef R, Primic-Žakelj M, Izarzugaza MI, Perucha J, Marcos-Gragera R, Galceran J, Ardanaz E, Schaffar R, Pring A, de Vries E. Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015. *J Eur Acad Dermatol Venereol*. 2014 Sep;28(9):1170-8.
4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018 Nov;68(6):394-424.
5. Whiteman DC, Green AC, Olsen CM. The Growing Burden of Invasive Melanoma: Projections of Incidence Rates and Numbers of New Cases in Six Susceptible Populations through 2031. *J Invest Dermatol*. 2016 Jun;136(6):1161-1171.
6. Liskay G, Kiss Z, Gyulai R, Oláh J, Holló P, Emri G, Csejtei A, Kenessey I, Benedek A, Polányi Z, Nagy-Erdei Z, Daniel A, Knollmayer K, Várnai M, Vokó Z, Nagy B, Rokszin G, Fábián I, Barcza Z, Polgár C. Changing Trends in Melanoma Incidence and Decreasing Melanoma Mortality in Hungary Between 2011 and 2019: A Nationwide Epidemiological Study. *Front Oncol*. 2021 Feb 12;10:612459.
7. Guy P, Thomas CC, Thompson T, Watson M, Massetti GM, Richardson LC, Centers for Disease Control and Prevention (CDC). Vital signs: melanoma incidence and mortality trends and projections - United States, 1982-2030. *MWR Morb Mortal Wkly Rep*. 2015 Jun 5;64(21):591-6.
8. Elder DE, Gimotty PA, Guerry D. Cutaneous melanoma: estimating survival and recurrence risk based on histopathologic features. *Dermatol Ther*. 2005 Sep-Oct;18(5):369-85.
9. Schuchter L, Schultz DJ, Synnestvedt M, Trock BJ, Guerry D, Elder DE, Elenitsas R, Clark WH, Halpern AC. A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group. *Ann Intern Med*. 1996 Sep 1;125(5):369-75.

10. Behbahani S, Maddukuri S, Cadwell JB, Lambert WC, Schwartz RA. Gender differences in cutaneous melanoma: Demographics, prognostic factors, and survival outcomes. *Dermatol Ther*. 2020 Nov;33(6):e14131. doi: 10.1111/dth.14131.
11. de Vries E, Nijsten TE, Visser O, Bastiaannet E, van Hattem S, Janssen-Heijnen ML, Coebergh JW. Superior survival of females among 10,538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site. *Ann Oncol*. 2008 Mar;19(3):583-9.
12. Forsea AM, Del Marmol V, de Vries E, Bailey EE, Geller AC. Melanoma incidence and mortality in Europe: new estimates, persistent disparities. *Br J Dermatol*. 2012 Nov;167(5):1124-30.
13. Barbaric J, Sekerija M, Agius D, Coza D, Dimitrova N, Demetriou A, Safaei Diba C, Eser S, Gavric Z, Primic-Zakelj M, Zivkovic S, Zvolsky M, Bray F, Coebergh JW, Znaor A. Disparities in melanoma incidence and mortality in South-Eastern Europe: Increasing incidence and divergent mortality patterns. Is progress around the corner? *Eur J Cancer*. 2016 Mar;55:47-55.
14. Donia M, Ellebaek E, Øllegaard TH, Duval L, Aaby JB, Hoejberg L, Køhler UH, Schmidt H, Bastholt L, Svane IM. The real-world impact of modern treatments on the survival of patients with metastatic melanoma. *Eur J Cancer*. 2019 Feb;108:25-32.
15. Cowey CL, Liu FX, Boyd M, Aguilar KM, Krepler C. Real-world treatment patterns and clinical outcomes among patients with advanced melanoma: A retrospective, community oncology-based cohort study (A STROBE-compliant article). *Medicine (Baltimore)*. 2019 Jul;98(28):e16328.
16. Uprety D, Bista A, Chennamadhavuni A, Niroula A, Jafri SIM, Smith A, Arjyal L. Survival trends among patients with metastatic melanoma in the pretargeted and the post-targeted era: a US population-based study. *Melanoma Res*. 2018 Feb;28(1):56-60.
17. Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. *Nat Rev Clin Oncol*. 2017 Aug;14(8):463-482.
18. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève J, Ogunbiyi OJ, Azevedo E Silva G, Chen WQ, Eser S, Engholm G, Stiller CA, Monnereau A, Woods RR, Visser O, Lim GH, Aitken J, Weir HK, Coleman MP; CONCORD Working Group. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3):

- analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *Lancet*. 2018 Mar 17;391(10125):1023-1075.
19. Gutiérrez-González E, López-Abente G, Aragonés N, Pollán M, Pastor-Barriuso R, Sánchez MJ, Pérez-Gómez B. Trends in mortality from cutaneous malignant melanoma in Spain (1982-2016): sex-specific age-cohort-period effects. *J Eur Acad Dermatol Venereol*. 2019 Aug;33(8):1522-1528.
 20. Dobry AS, Zogg CK, Hodi FS, Smith TR, Ott PA, Iorgulescu JB. Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. *Cancer Immunol Immunother*. 2018 Dec;67(12):1833-1844.
 21. Berk-Krauss J, Stein JA, Weber J, Polsky D, Geller AC. New Systematic Therapies and Trends in Cutaneous Melanoma Deaths Among US Whites, 1986-2016. *Am J Public Health*. 2020 May;110(5):731-733.
 22. Brunssen A, Waldmann A, Eisemann N, Katalinic A. Impact of skin cancer screening and secondary prevention campaigns on skin cancer incidence and mortality: A systematic review. *J Am Acad Dermatol*. 2017 Jan;76(1):129-139.e10.
 23. Iannacone MR, Green AC. (2014). Towards skin cancer prevention and early detection: evolution of skin cancer awareness campaigns in Australia. *Melanoma Manag* 1(1):75–84.
 24. Youl PH, Soyer HP, Baade PD, Marshall AL, Finch L, Janda M (2015). Can skin cancer prevention and early detection be improved via mobile phone text messaging? A randomised, attention control trial. *Prev Med* 71:50–56.
 25. Tabbakh T, Volkov A, Wakefield M, Dobbinson S (2019). Implementation of the SunSmart Program and Population Sun Protection Behaviour in Melbourne, Australia: Results From Cross-Sectional Summer Surveys From 1987 to 2017. *PLoS Med* 16(10):e1002932.
 26. del Marmol V, de Vries E, van der Endt, J, Roseeuw D, Vandaele M, Pirard C, et al. (2006). Evaluation of 7 years of Euromelanoma day, a voluntary melanoma screening campaign in Belgium. *Melanoma Res* 16:S22–S23.
 27. Suppa M, Altomare G, Cannavò SP, Capizzi R, Catricalà C, Colombo E, et al. (2014). The Italian Euromelanoma Day: evaluation of results and implications for future prevention campaigns. *Int J Dermatol* 53(6):699–706.

28. Morgese F, Sampaolesi C, Torniai M, Conti A, Ranallo N, Giacchetti A, Serresi S, Onofri A, Burattini M, Ricotti G, Berardi R. Gender Differences and Outcomes in Melanoma Patients. *Oncol Ther*. 2020 Jun;8(1):103-114.
29. Scoggins CR, Ross MI, Reintgen DS, Noyes RD, Goydos JS, Beitsch PD, Urist MM, Ariyan S, Sussman JJ, Edwards MJ, Chagpar AB, Martin RC, Stromberg AJ, Hagendoorn L, McMasters KM; Sunbelt Melanoma Trial. Gender-related differences in outcome for melanoma patients. *Ann Surg*. 2006 May;243(5):693-8; discussion 698-700.
30. Ócsai H, Ócsai H, Battyáni Z, Emri G, Liskay G, Somlai B, et al. EuroMelanoma Nappal szerzett tapasztalataink az elmúlt 5 évben (2009- 2013). *Magyar Onkológia* (2013) 57(5):68.
31. Hungarian regulation: 60/2003 ESZCSM rendelet az egészségügyi szolgáltatások nyújtásához szükséges szakmai minimumfeltételekről [Regulation on the professional minimum requirements on providing health care].
32. Regulation on certain questions of social insurance financing of health care services : (9/1993. (IV. 2.) NM rendelet az egészségügyi szakellátás társadalombiztosítási finanszírozásának egyes kérdéseiről [Regulation on certain questions of social insurance financing of health care services].
33. Kandolf Sekulovic L, Guo J, Agarwala S, Hauschild A, McArthur G, Cinat G, Wainstein A, Caglevic C, Lorigan P, Gogas H, Alvarez M, Duncombe R, Lebbe C, Peris K, Rutkowski P, Stratigos A, Forsea AM, De La Cruz Merino L, Kukushkina M, Dummer R, Hoeller C, Gorry C, Bastholt L, Herceg D, Neyns B, Vieira R, Arenberger P, Bylaite-Bucinskiene M, Babovic N, Banjin M, Putnik K, Todorovic V, Kirov K, Ocvirk J, Zhukavets A, Ymeri A, Stojkovski I, Garbe C. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. *Eur J Cancer*. 2018 Nov;104:201-209
34. Balatoni T, Liskay G, Miklós Z, Kásler M. A melanoma malignum epidemiológiája (Klinikai tapasztalatok az Országos Onkológiai Intézetben) [Epidemiology of malignant melanoma (Clinical experience at the National Institute of Oncology in Hungary)]. *Orv Hetil* (2011) 152(25):1000–6. doi: 10.1556/OH.2011.29148.
35. Wróbel S, Przybyło M, Stępień E. The Clinical Trial Landscape for Melanoma Therapies. *J Clin Med*. 2019 Mar 15;8(3):368. doi: 10.3390/jcm8030368.

36. Sun J, Kirichenko DA, Zager JS, Eroglu Z. The emergence of neoadjuvant therapy in advanced melanoma. *Melanoma Manag.* 2019 Oct 18;6(3):MMT27. doi: 10.2217/mmt-2019-0007.
37. Liszkay G. Klinikai vizsgálatok eredményei és törzskönyvezett gyógyszerek az előrehaladott melanoma immunterápiájában [Clinical studies and accepted therapies of advanced melanoma]. *Magy Onkol.* 2016 Mar 2;60(1):11-5. Hungarian.
38. European Medicines Agency, Medicines, downloaded 02/11/2022, <https://www.ema.europa.eu/en/medicines>
39. Cancer Research UK. Melanoma skin cancer survival statistics. Available at: <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/melanoma-skin-cancer/survival#heading=Two> [accessed March 30, 2021]
40. Hieken TJ, Glasgow AE, Enninga EAL, Kottschade LA, Dronca RS, Markovic SN, Block MS, Habermann EB. Sex-Based Differences in Melanoma Survival in a Contemporary Patient Cohort. *J Womens Health (Larchmt).* 2020 Sep;29(9):1160-1167.
41. Downing A, Newton-Bishop JA, Forman D. Recent trends in cutaneous malignant melanoma in the Yorkshire region of England; incidence, mortality and survival in relation to stage of disease, 1993-2003. *Br J Cancer.* 2006 Jul 3;95(1):91-5.
42. Liu W, Dowling JP, Murray WK, McArthur GA, Thompson JF, Wolfe R, Kelly JW. Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. *Arch Dermatol.* 2006 Dec;142(12):1551-8.
43. Devos SA, Baeyens K, Van Hecke L. Sunscreen use and skin protection behavior on the Belgian beach. *Int J Dermatol.* 2003 May;42(5):352-6.
44. Titus LJ, Clough-Gorr K, Mackenzie TA, Perry A, Spencer SK, Weiss J, Abrahams-Gessel S, Ernstoff MS. Recent skin self-examination and doctor visits in relation to melanoma risk and tumour depth. *Br J Dermatol.* 2013 Mar;168(3):571-6.
45. Joosse A, de Vries E, Eckel R, Nijsten T, Eggermont AM, Hölzel D, Coebergh JW, Engel J; Munich Melanoma Group. Gender differences in melanoma survival: female patients have a decreased risk of metastasis. *J Invest Dermatol.* 2011 Mar;131(3):719-26.
46. Bellenghi M, Puglisi R, Pontecorvi G, De Feo A, Carè A, Mattia G. Sex and Gender Disparities in Melanoma. *Cancers (Basel).* 2020 Jul 7;12(7):1819. doi: 10.3390/cancers12071819.

47. Roh MR, Eliades P, Gupta S, Grant-Kels JM, Tsao H. Cutaneous melanoma in women. *Int J Womens Dermatol*. 2017 Feb 16;3(1 Suppl):S11-S15.
48. Várnai M, Kiss Z, Gyulai R, Oláh J, Holló P, Emri G, Csejtei A, Kenessey I, Benedek A, Polányi Z, Nagy-Erdei Z, Dániel A, Knollmayer K, Roksztin G, Fábíán I, Barcza Z, Polgár C, Nagy B, Liskay G, Vokó Z. Improving Quality Indicator of Melanoma Management - Change of Melanoma Mortality-to-Incidence Rate Ratio Based on a Hungarian Nationwide Retrospective Study. *Front Oncol*. 2021 Oct 19;11:745550.
49. Plym A, Ullenhag GJ, Breivald M, Lambe M, Berglund A. Clinical characteristics, management and survival in young adults diagnosed with malignant melanoma: A population-based cohort study. *Acta Oncol*. 2014 May;53(5):688-96.
50. Cancer Research UK. Melanoma skin cancer survival statistics. Available at: <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/melanoma-skin-cancer/survival#heading-One> [accessed March 31, 2021]
51. Macdonald JB, Dueck AC, Gray RJ, Wasif N, Swanson DL, Sekulic A, Pockaj BA. Malignant melanoma in the elderly: different regional disease and poorer prognosis. *J Cancer*. 2011;2:538-43.
52. Kruijff S, Bastiaannet E, Francken AB, Schaapveld M, van der Aa M, Hoekstra HJ. Breslow thickness in the Netherlands: a population-based study of 40 880 patients comparing young and elderly patients. *Br J Cancer*. 2012 Jul 24;107(3):570-4.
53. Tas F, Erturk K. Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival. *Mol Clin Oncol*. 2017 Dec;7(6):1083-1088.
54. Ciocan D, Barbe C, Aubin F, Granel-Brocard F, Lipsker D, Velten M, Dalac S, Truchetet F, Michel C, Mitschler A, Arnoult G, Buemi A, Dalle S, Bernard P, Woronoff AS, Grange F. Distinctive features of melanoma and its management in elderly patients: a population-based study in France. *JAMA Dermatol*. 2013 Oct;149(10):1150-7.
55. Tsai S, Balch C, Lange J. Epidemiology and treatment of melanoma in elderly patients. *Nat Rev Clin Oncol*. 2010 Mar;7(3):148-52.
56. Montecino-Rodriguez E, Berent-Maoz B, Dorshkind K. Causes, consequences, and reversal of immune system aging. *J Clin Invest*. 2013;123(3):958-965. doi:10.1172/JCI64096

